Citius Pharmaceuticals to Participate in Upcoming EF Hutton and H.C. Wainwright Investor Conferences
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Citius Pharmaceuticals, Inc. (Nasdaq: CTXR) will participate in the upcoming EF Hutton and H.C. Wainwright investor conferences. CEO Leonard Mazur will host one-on-one investor meetings at the EF Hutton Annual Global Conference on May 15, 2024, and present at the H.C. Wainwright BioConnect Investor Conference on May 20, 2024.
Details
News Market Reaction – CTXR
The recorded move for CTXR in the trading session of this news was -0.91%.
Data tracked by StockTitan Argus. Session date unavailable.
AI-generated analysis. How Rhea-AI works. Not financial advice.
EF Hutton Annual Global Conference Details:
Format: | In-person one-on-one meetings (no general presentations) |
Location: | The Plaza Hotel, |
Registration: | Visit the conference website |
H.C. Wainwright 2nd Annual BioConnect Investor Conference Details:
Presentation*: | 3:30 p.m. ET on Monday, May 20th; live streaming available |
Format: | Presentations and one-on-one meetings |
Location: | Nasdaq Global Headquarters, |
Registration: | Visit the conference website |
*Please note that the presentation date and time are subject to change. Participants should refer to the final program agenda for up-to-date information.
About Citius Pharmaceuticals, Inc.
Citius Pharma is a late-stage biopharmaceutical company dedicated to the development and commercialization of first-in-class critical care products. The Company's diversified pipeline includes two late-stage product candidates. At the end of 2023, Citius completed enrollment in a Phase 3 pivotal superiority trial of Mino-Lok®, an antibiotic lock solution to salvage catheters in patients with catheter-related bloodstream infections. The Biologics License Application for LYMPHIR™, a novel IL-2R immunotherapy for an initial indication in cutaneous T-cell lymphoma, is currently under review by the FDA with August 13, 2024 assigned as the PDUFA target action date. Citius previously announced plans to form Citius Oncology, a standalone publicly traded company with LYMPHIR as its primary asset. LYMPHIR received orphan drug designation by the FDA for the treatment of CTCL and PTCL. In addition, Citius completed enrollment in its Phase 2b trial of CITI-002 (Halo-Lido), a topical formulation for the relief of hemorrhoids. For more information, please visit www.citiuspharma.com.
Investor Contact:
Ilanit Allen
ir@citiuspharma.com
908-967-6677 x113
View original content to download multimedia:https://www.prnewswire.com/news-releases/citius-pharmaceuticals-to-participate-in-upcoming-ef-hutton-and-hc-wainwright-investor-conferences-302141737.html
SOURCE Citius Pharmaceuticals, Inc.
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
